Success Metrics

Clinical Success Rate
77.8%

Based on 7 completed trials

Completion Rate
78%(7/9)
Active Trials
1(8%)
Results Posted
29%(2 trials)
Terminated
2(17%)

Phase Distribution

Ph phase_2
6
50%
Ph phase_1
2
17%
Ph phase_4
1
8%
Ph phase_3
1
8%

Phase Distribution

2

Early Stage

6

Mid Stage

2

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
2(20.0%)
Phase 2Efficacy & side effects
6(60.0%)
Phase 3Large-scale testing
1(10.0%)
Phase 4Post-market surveillance
1(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

70.0%

7 of 10 finished

Non-Completion Rate

30.0%

3 ended early

Currently Active

1

trials recruiting

Total Trials

12

all time

Status Distribution
Active(1)
Completed(7)
Terminated(3)
Other(1)

Detailed Status

Completed7
Terminated2
Withdrawn1
Recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
1
Success Rate
77.8%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (20.0%)
Phase 26 (60.0%)
Phase 31 (10.0%)
Phase 41 (10.0%)

Trials by Status

withdrawn18%
recruiting18%
unknown18%
completed758%
terminated217%

Recent Activity

1 active trials
Showing 5 of 12
recruiting

Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia

NCT05282108
completedphase_2

Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)

NCT00744081
terminatedphase_2

Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response

NCT00210119
completedphase_3

Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors

NCT00293124
completedphase_1

Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body

NCT01795716
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT05282108

Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia

Recruiting
NCT00744081Phase 2

Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)

Completed
NCT00210119Phase 2

Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response

Terminated
NCT00293124Phase 3

Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors

Completed
NCT01795716Phase 1

Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body

Completed
NCT01613053

Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study Termination

Unknown
NCT01653314Phase 1

Megavec 400 mg (Imatinib Mesylate) in Healthy Adult Male Volunteers

Completed
NCT00159016Phase 2

Role of Glivec in Patients With Tumor Cells Positive for C-kit or PDGFR; a Multi Center Study.

Withdrawn
NCT01153750Phase 2

Efficacy of Imatinib and 5-FU/Leucovorin in Patients With Advanced Carcinoma of the Gallbladder and Bile Duct

Completed
NCT00390897Phase 4

Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia

Completed
NCT00388895Phase 2

Glivec in Ph Positive Lymphoblastic Leukemia

Completed
NCT00180830Phase 2

Glivec Phase II Pediatric Study

Terminated

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12